Herbas VPB

Print
EN | LT
Supplementary protection
LT - Tirpios CTLA4 mutantinės molekulės ir jų panaudojimas
EN - SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF
SPC
(11) Number of the document C 1248802
(68) Number of the document 1248802
(21) Application number for Supplementary Protection Certificate PA 2011 014
(22) Date of filing the application 2011-11-14
(41) Date of publication of the application 2011-12-27
Date of publication of SPC 2012-08-27
(24) Date of coming into effect of SPC 2021-05-24
Applicant
(71) Bristol-Myers Squibb Company, Lawrenceville-Princeton Road P.O. Box 4000, Princeton NJ 08543-4000, US
Grantee
(73) Bristol-Myers Squibb Company, Lawrenceville-Princeton Road P.O. Box 4000, Princeton NJ 08543-4000, US
Attorney or representative
(74) Reda ŽABOLIENĖ, METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius, LT
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
(93) EU/1/11/694/001, 2011 06 17 EU/1/11/694/002, 2011-06-17
Calculated date of expiry of the SPC
(94) 2026-05-24
Name of the product protected by the basic patent
(95) Belataceptum
Last renewal fee
Payment date Validity (years) Amount
2025-04-22 5 347.00 EUR
Legal status
SPC granted
Last update date 2025-04-23